Merz Pharma Group has acquired the cosmetics, over-the-counter, and prescription skin care businesses of Swiss dermatology company Neocutis. The company's North American division will integrate marketing of Neocutis' line of physician-dispensed topical skin care products in the US. “Neocutis' line of topical skin care products complements our current portfolio of aesthetic injectable products and expands our ability to provide patients and physicians with innovative, high-quality aesthetic products along the full continuum of care,” President and CEO of Merz North America Bill Humphries said in a statement. Financial terms of the acquisition were not disclosed. The deal also comes several weeks after Merz licensed a topical, medicated foam technology from Israel-based company Foamix.